Key result
RAAS inhibitors provide blood pressure-independent organ protection by suppressing inflammation and oxidative stress.
Why the study?
Systematic comparisons of inflammatory and oxidative stress regulatory effects across distinct RAAS inhibitor classes and integration of recent evidence were lacking.
Do RAAS inhibitors reduce inflammatory responses and oxidative stress through specific molecular mechanisms?
Do RAAS inhibitors reduce inflammatory responses and oxidative stress through specific molecular mechanisms?
This review consolidates molecular and clinical evidence showing that the organ-protective benefits of RAAS inhibitors extend beyond blood pressure reduction, primarily through the modulation of inflammatory responses and oxidative stress.
May support RAAS inhibitor selection for multi-organ protection in inflammatory states; extends mechanistic evidence across systems but requires prospective trials.
The renin-angiotensin-aldosterone system (RAAS) inhibitors serve as cornerstone pharmacotherapies for chronic conditions including hypertension, heart failure, and chronic kidney disease. Accumulating evidence over recent years has demonstrated that their target organ-protective effects cannot be fully attributed to blood pressure-lowering actions alone; instead, the modulation of inflammatory responses and oxidative stress emerges as a core mechanism underpinning their extra-antihypertensive benefits. However, systematic comparisons of such effects across distinct classes of RAAS inhibitors and integration of the latest evidence remain lacking. This review focuses on the molecular regulatory network of the dual RAAS axes, systematically dissecting the specific molecular mechanisms by which the canonical ACE-AngII-AT1R axis mediates tissue injury—via activation of the NLRP3 inflammasome, NADPH oxidase, and NF-κB signaling pathways—while the protective ACE2-Ang(1–7)-MasR axis exerts anti-inflammatory and antioxidant effects. A cross-class comparison is conducted to evaluate the divergent effects of five clinically prevalent RAAS inhibitor classes (ACE inhibitors [ACEI], angiotensin receptor blockers [ARB], direct renin inhibitors [DRI], angiotensin receptor-neprilysin inhibitors [ARNI], and mineralocorticoid receptor antagonists [MRA]) on the regulation of inflammation and oxidative stress. By synthesizing the latest evidence from basic science and clinical studies over the past decade, we summarize the distinct organ-protective profiles of these agents across various target organs affected by cardiovascular disease, chronic kidney disease, pulmonary disorders, neurological conditions, rheumatoid arthritis, and osteoporosis. Finally, addressing the limitations and inconsistencies within existing literature, this article proposes future research directions, strategies for optimizing combination therapies, and refined clinical trial designs to enhance the clinical application of RAAS inhibitors and facilitate the development of novel organ-protection paradigms.
No takes yet. Share an insight, caveat, or question.
Yin et al. (2026) conducted a review in Cardiovascular, renal, and inflammatory diseases. RAAS inhibitors (ACEIs, ARBs, DRIs, ARNIs, and MRAs) was evaluated. RAAS inhibitors exhibit target organ-protective effects beyond blood pressure lowering by modulating inflammatory responses and oxidative stress, primarily through the protective ACE2-Ang(1–7)-MasR axis and inhibition of the canonical RAAS pathway.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: